INS and type 2 diabetes mellitus: A sub-study of this large multicentre trial in newly diagnosed individuals with T2D showed that compared to SU and insulin, metformin was associated with a reduction in any diabetes-related endpoint including myocardial infarction (MI) and heart failure (HF) (p = 0.0034), all-cause mortality (p = 0.021) and stroke (p = 0.032) over a mean duration of 10.7 years.